Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis reports Q2 2026 results with TRYNGOLZA launch momentum, Angelman Phase 3 enrollment complete
Filed July 29, 2026 · Period ending July 29, 2026 · ~1 min read
Key Changes
-
high
CARDIO-TTRansform Phase 3 trial of eplontersen for ATTR-CM missed primary endpoint in overall population, though showed nominal significance in monotherapy subgroup; results to be presented at ESC Congress August 2026.
Exhibit 99.1 view on EDGAR → -
high
TRYNGOLZA generated $5M Q2 sales and $32M first-half sales; company on track for $100-110M full-year 2026 sales, with sHTG launch showing early momentum following June 2026 FDA approval.
Exhibit 99.1 view on EDGAR → -
high
DAWNZERA generated $26M Q2 sales (up 63% vs Q1) and $42M first-half sales; company on track for $110-120M full-year 2026 sales.
Exhibit 99.1 view on EDGAR → -
high
Q2 2026 total revenue $268M with operating loss of $102M GAAP ($57M non-GAAP); first-half revenue $514M with operating loss of $220M GAAP ($131M non-GAAP). Company reaffirms 2026 guidance and 2028 cashflow breakeven target.
Exhibit 99.1 view on EDGAR → -
medium
Completed enrollment in Phase 3 REVEAL trial of obudanersen for Angelman syndrome; data anticipated second half of 2027.
Exhibit 99.1 view on EDGAR →
Summary
Ionis reported Q2 2026 results showing commercial traction in its marketed products alongside a setback in a partnered late-stage trial. The company generated $268 million in total revenue for the quarter, with an operating loss of $102 million on a GAAP basis ($57 million non-GAAP).
TRYNGOLZA's severe hypertriglyceridemia launch is gaining momentum following June 2026 FDA approval, with $5 million in Q2 sales contributing to $32 million in first-half revenue. DAWNZERA sales accelerated 63% quarter-over-quarter to $26 million, putting both products on track to meet their full-year guidance ranges of $100-110 million and $110-120 million respectively.
The Phase 3 CARDIO-TTRansform trial of partnered medicine eplontersen for ATTR-CM missed its primary composite endpoint in the overall population, though it showed nominal significance in a pre-specified monotherapy subgroup and maintained a favorable safety profile. Full results will be presented at the ESC Congress in August 2026. Despite this outcome, Ionis reaffirmed its 2026 financial guidance and 2028 cashflow breakeven target. The company also completed enrollment in the Phase 3 REVEAL trial of obudanersen for Angelman syndrome, with data expected in the second half of 2027. Investors should monitor the detailed CARDIO-TTRansform presentation at ESC for implications on eplontersen's commercial potential and Ionis's royalty stream.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Ionis disclosed Q2 2026 financial results via press release, presenting both GAAP and non-GAAP metrics excluding stock compensation.
Added in current filing · verify on EDGAR →
On July 29, 2026, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026.
Ionis announced its second quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures; those are in the attached press release exhibit. This filing serves as the formal notification that results have been disclosed.
Added in current filing · verify on EDGAR →
In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects.
Ionis presents both GAAP and non-GAAP financial metrics, with the non-GAAP figures excluding stock-based compensation expense and related tax effects. The company states this exclusion helps investors assess historical performance and project future operating results and cash flows. Investors should review both sets of metrics to understand the impact of equity compensation on reported profitability.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Phase 3 CARDIO-TTRansform study of eplontersen for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) missed the primary composite endpoint in the overall population, demonstrated nominal significance in the pre-specified monotherapy population, and a favorable safety and tolerability profile
The Phase 3 CARDIO-TTRansform study of partnered medicine eplontersen (WAINUA) for ATTR-CM missed the primary composite endpoint in the overall population, though it demonstrated nominal significance in the pre-specified monotherapy population and a favorable safety and tolerability profile. Results will be presented at the ESC Congress in August 2026. Despite this outcome, the company remains on track to achieve 2026 financial guidance.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 30, 2026 · How we verify